

Manuel Romero-Gómez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1674573/publications.pdf>

Version: 2024-02-01

547
papers

35,632
citations

6233

80
h-index

4101

175
g-index

602
all docs

602
docs citations

602
times ranked

28371
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
3	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2015, 149, 367-378.e5.	0.6	1,592
4	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.	13.9	1,580
5	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
6	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
7	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	847
8	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
9	Treatment of NAFLD with diet, physical activity and exercise. <i>Journal of Hepatology</i> , 2017, 67, 829-846.	1.8	838
10	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
11	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
12	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014, 370, 1993-2001.	13.9	752
13	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005, 128, 636-641.	0.6	699
14	ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. <i>New England Journal of Medicine</i> , 2014, 370, 1983-1992.	13.9	669
15	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	595
16	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	2.4	559
17	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.6	536
18	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524

#	ARTICLE	IF	CITATIONS
19	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
20	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460.	0.6	361
21	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001, 96, 2718-2723.	0.2	346
22	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
23	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
24	Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. <i>Hepatology</i> , 2007, 45, 879-885.	3.6	282
25	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
26	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	3.6	267
27	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	3.6	266
28	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	0.6	248
29	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005, 41, 779-789.	3.6	245
30	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017, 152, 1449-1461.e7.	0.6	209
31	EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 78, 711-721.	0.5	203
32	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
33	Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. <i>Liver International</i> , 2009, 29, 629-635.	1.9	196
34	Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 437-447.	1.8	196
35	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
36	Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. <i>Hepatology</i> , 2010, 52, 33-37.	3.6	183

#	ARTICLE	IF	CITATIONS
37	Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression. <i>Journal of Proteome Research</i> , 2012, 11, 2521-2532.	1.8	183
38	Glutathione <i>S</i> -transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596.	3.6	181
39	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 48, 721-727.	1.8	175
40	Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1456-1465.	0.2	163
41	Interferon-Î» rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015, 6, 6422.	5.8	156
42	Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 780-789.	1.9	150
43	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
44	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
45	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
46	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.	3.6	143
47	Insulin resistance and hepatitis C. <i>World Journal of Gastroenterology</i> , 2006, 12, 7075.	1.4	139
48	Treatment of insulin resistance with metformin in naÃƒve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708.	3.6	136
49	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
50	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.	3.6	134
51	Power Doppler Ultrasonography Assessment of Entheses in Spondyloarthropathies: Response to Therapy of Enteseal Abnormalities. <i>Journal of Rheumatology</i> , 2010, 37, 2110-2117.	1.0	125
52	The role of nutrition in nonâ€alcoholic fatty liver disease: Pathophysiology and management. <i>Liver International</i> , 2020, 40, 102-108.	1.9	125
53	EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. <i>Journal of Hepatology</i> , 2022, 77, 807-824.	1.8	124
54	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123

#	ARTICLE	IF	CITATIONS
55	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018, 69, 1335-1348.	1.8	121
56	Metabolomicâ€­based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018, 2, 807-820.	2.0	117
57	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
58	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
59	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	6.1	113
60	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
61	Minimal Hepatic Encephalopathy and Critical Flicker Frequency Are Associated With Survival of Patients With Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 1483-1489.	0.6	108
62	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
63	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016, 7, 12757.	5.8	104
64	Development and Validation of Hepamet Fibrosis Scoring Systemâ€­A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
65	Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 7327.	1.4	103
66	Review article: <scp>HCV</scp> genotype 3 â€­ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	1.9	103
67	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	3.6	101
68	Clinical management of drugâ€­drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800.	1.8	100
69	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	1.8	100
70	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.	3.6	97
71	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	0.6	97
72	Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2004, 41, 49-54.	1.8	96

#	ARTICLE	IF	CITATIONS
73	Meta-analysis: insulin resistance and sustained virological response in hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 297-305.	1.9	96
74	HLA antigens in chronic hepatitis C: Relationship with interferon response and severity of liver injury. <i>Journal of Hepatology</i> , 2000, 32, 129.	1.8	95
75	Serum Leptin Levels Correlate With Hepatic Steatosis in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1135-1141.	0.2	94
76	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90
77	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020, 115, 989-1002.	0.2	87
78	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	9.4	86
79	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	3.6	83
80	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
81	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. <i>PLoS ONE</i> , 2013, 8, e68111.	1.1	81
82	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. <i>Scientific Reports</i> , 2016, 6, 31777.	1.6	81
83	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2085-2092.e1.	2.4	79
84	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	3.6	78
85	Association between vitamin D and hepatitis C virus infection: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2013, 19, 5917.	1.4	77
86	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
87	Gut ammonia production and its modulation. <i>Metabolic Brain Disease</i> , 2009, 24, 147-157.	1.4	75
88	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	1.8	74
89	Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.	1.8	72
90	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	8.2	72

#	ARTICLE	IF	CITATIONS
91	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
92	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
93	Documento de consenso. Manejo de la enfermedad hepÃ¡tica grasa no alcohÃ³lica (EHGNA). GuÃ­a de prÃ¡ctica clÃ­nica. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2018, 41, 328-349.	0.2	71
94	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
95	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with <scp>NAFLD</scp> using the <scp>SAF</scp> score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 877-889.	1.9	70
96	The effects of metabolic status on nonâ€alcoholic fatty liver diseaseâ€related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	1.9	70
97	Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients With Cirrhosis. <i>Annals of Internal Medicine</i> , 2010, 153, 281.	2.0	68
98	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020, 31, 605-622.e10.	7.2	68
99	A polymorphism in the Irisin-encoding gene (FND5) associates with hepatic steatosis by differential miRNA binding to the 3â€™UTR. <i>Journal of Hepatology</i> , 2019, 70, 494-500.	1.8	67
100	Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2002, 37, 781-787.	1.8	66
101	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	3.6	66
102	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	1.8	66
103	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
104	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001, 96, 2718-2723.	0.2	64
105	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	1.8	64
106	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 107, 10-6.	0.1	64
107	Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 469-477.	0.6	63
108	Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. <i>American Journal of Gastroenterology</i> , 2010, 105, 2164-2172.	0.2	62

#	ARTICLE	IF	CITATIONS
109	Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance. International Journal of Molecular Sciences, 2014, 15, 23163-23178.	1.8	61
110	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut, 2002, 51, 434-439.	6.1	60
111	Steatosis and insulin resistance in hepatitis C: A way out for the virus?. World Journal of Gastroenterology, 2009, 15, 5014.	1.4	60
112	Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. American Journal of Clinical Nutrition, 2020, 112, 1240-1251.	2.2	59
113	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology, 2020, 73, 17-25.	1.8	59
114	Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology, 2004, 39, 939-943.	3.6	58
115	Acute liver injury associated with the use of ebrotidine, a new H ₂ -receptor antagonist. Journal of Hepatology, 1999, 31, 641-646.	1.8	55
116	Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy. PLoS ONE, 2012, 7, e49279.	1.1	55
117	Serum Metabolic Signature of Minimal Hepatic Encephalopathy by ¹ H-Nuclear Magnetic Resonance. Journal of Proteome Research, 2010, 9, 5180-5187.	1.8	54
118	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Reports, 2020, 2, 100142.	2.6	53
119	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology, 2006, 43, 72-80.	3.6	52
120	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with nonalcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 332-344.	1.9	52
121	Antiphospholipid Antibodies Are Related to Portal Vein Thrombosis in Patients with Liver Cirrhosis. Journal of Clinical Gastroenterology, 2000, 31, 237-240.	1.1	51
122	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology, 2008, 47, 810-816.	3.6	51
123	Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver International, 2011, 31, 443-460.	1.9	51
124	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology, 2016, 63, 1875-1887.	3.6	50
125	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 2014, 44, 65-73.	1.7	49
126	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	2.4	49

#	ARTICLE	IF	CITATIONS
127	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 392-398.	0.5	47
128	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	1.9	47
129	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	2.4	47
130	Pseudomembranous Colitis Induced by Diclofenac. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 228.	1.1	45
131	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
132	Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014, 106, 246-54.	0.1	44
133	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 839-845.	2.8	42
134	HLA-C and KIR Genes in Hepatitis C Virus Infection. <i>Human Immunology</i> , 2005, 66, 1106-1109.	1.2	41
135	4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS. <i>Journal of Hepatology</i> , 2011, 54, S2.	1.8	40
136	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <i>Psychopharmacology</i> , 2016, 233, 3947-3952.	1.5	40
137	Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1305-1312.	1.1	40
138	Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. <i>World Journal of Gastroenterology</i> , 2006, 12, 2406.	1.4	40
139	PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.	3.6	39
140	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
141	Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. <i>Digestive and Liver Disease</i> , 2001, 33, 698-702.	0.4	38
142	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. <i>World Journal of Hepatology</i> , 2015, 7, 2497.	0.8	38
143	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
144	Role of Phosphate-Activated Glutaminase in the Pathogenesis of Hepatic Encephalopathy. <i>Metabolic Brain Disease</i> , 2005, 20, 319-325.	1.4	37

#	ARTICLE	IF	CITATIONS
145	Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. <i>Journal of Hepatology</i> , 2014, 60, 545-553.	1.8	37
146	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1290-1295.	0.8	37
147	An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat Western-type diet in mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600549.	1.5	37
148	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 291-295.	1.4	36
149	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	2.6	36
150	Use of HOMA-IR in hepatitis C. <i>Journal of Viral Hepatitis</i> , 2011, 18, 675-684.	1.0	35
151	Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013, 59, 1323-1330.	1.8	35
152	Serum selenium levels and oxidative balance as differential markers in hepatic damage caused by alcohol. <i>Life Sciences</i> , 2014, 94, 158-163.	2.0	35
153	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014, 61, 235-241.	1.8	35
154	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	2.4	35
155	Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G373-G381.	1.6	34
156	Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 829-844.	1.9	34
157	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 718-725.	1.4	34
158	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 31421.	1.6	33
159	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , 2018, 13, e0191805.	1.1	33
160	What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 109-112.	0.7	33
161	Infliximab induces remission of pyoderma gangrenosum. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 907.	0.8	32
162	Clinical trial: pharmacodynamics and pharmacokinetics of retreatment with fixed-dose induction of peginterferon 1a in hepatitis C virus genotype 1 true non-responder patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1131-1138.	1.9	32

#	ARTICLE	IF	CITATIONS
163	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. <i>Annals of Hepatology</i> , 2013, 12, 420-430.	0.6	32
164	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patientâ€™s Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	2.0	32
165	Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin. <i>American Journal of Gastroenterology</i> , 2011, 106, 1246-1254.	0.2	31
166	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 547-556.	1.3	31
167	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. <i>World Journal of Hepatology</i> , 2015, 7, 1105.	0.8	31
168	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021, 73, 103661.	2.7	31
169	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	3.6	31
170	Role of diabetes mellitus on hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013, 28, 277-279.	1.4	30
171	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2014, 147, 119-131.e3.	0.6	30
172	Simeprevir in combination with sofosbuvir in treatment-naïve and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 468-475.	1.9	30
173	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 283-290.	0.4	29
174	Acute hepatitis due to <i>Mycoplasma pneumoniae</i> infection without lung involvement in adult patients. <i>Journal of Hepatology</i> , 2006, 44, 827-828.	1.8	28
175	The Hepatitis C Virus Modulates Insulin Signaling Pathway In Vitro Promoting Insulin Resistance. <i>PLoS ONE</i> , 2012, 7, e47904.	1.1	28
176	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 10064.	1.4	28
177	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017, 37, 212-223.	1.9	28
178	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019, 103, 28-38.	0.5	28
179	Wilson's disease: Revisiting an old friend. <i>World Journal of Hepatology</i> , 2021, 13, 634-649.	0.8	28
180	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28

#	ARTICLE	IF	CITATIONS
181	European "NAFLD Preparedness Index" " Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	2.6	27
182	Hla Class I B44 Is Associated With Sustained Response To Interferon + Ribavirin Therapy in Patients With Chronic Hepatitis C. American Journal of Gastroenterology, 2003, 98, 1621-1626.	0.2	26
183	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. World Journal of Gastroenterology, 2018, 24, 5223-5233.	1.4	26
184	SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut, 2004, 53, 446-450.	6.1	25
185	Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. European Journal of Gastroenterology and Hepatology, 2012, 24, 535-542.	0.8	25
186	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. Journal of Infection, 2013, 67, 185-193.	1.7	25
187	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1611-1618.	1.4	25
188	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. Journal of Clinical Gastroenterology, 2016, 50, 779-789.	1.1	25
189	Eliminaci3n de la hepatitis C. Documento de posicionamiento de la Asociaci3n Espa±ola para el Estudio del HÃgado (AEEH). GastroenterologÃa Y HepatologÃa, 2019, 42, 579-592.	0.2	25
190	Hepatotoxicity induced by clopidogrel. Journal of Hepatology, 2004, 40, 560-562.	1.8	24
191	Hepatitis C virus infection alters lipid metabolism depending on <sc>IL</sc>28B polymorphism and viral genotype and modulates gene expression <i>in vivo</i> and <i>in vitro</i>. Journal of Viral Hepatitis, 2014, 21, 19-24.	1.0	24
192	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2819-2821.	2.4	24
193	Critical flicker frequency: It is time to break down barriers surrounding minimal hepatic encephalopathy. Journal of Hepatology, 2007, 47, 10-11.	1.8	23
194	Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. International Journal of Infectious Diseases, 2018, 67, 114-117.	1.5	23
195	Pharmacotherapy of hepatic encephalopathy in cirrhosis. Expert Opinion on Pharmacotherapy, 2010, 11, 1317-1327.	0.9	22
196	Assessing cardiovascular risk in hepatitis C: An unmet need. World Journal of Hepatology, 2015, 7, 2214.	0.8	22
197	Use of Steatotic Grafts in Liver Transplantation: Current Status. Liver Transplantation, 2019, 25, 771-786.	1.3	22
198	Minimal Hepatic Encephalopathy. Clinics in Liver Disease, 2020, 24, 209-218.	1.0	22

#	ARTICLE	IF	CITATIONS
199	Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. Revista Espanola De Enfermedades Digestivas, 2006, 98, 605-15.	0.1	22
200	Acute Hepatitis Related to Omeprazole. American Journal of Gastroenterology, 1999, 94, 1119-1120.	0.2	21
201	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. American Journal of Gastroenterology, 2004, 99, 2150-2157.	0.2	21
202	Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clinical and Translational Gastroenterology, 2020, 11, e00203.	1.3	21
203	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic <scp>HCV</scp> infection: Results from the Spanish <scp>HEPA</scp>â€ realâ€world cohort. Journal of Viral Hepatitis, 2019, 26, 55-64.	1.0	20
204	Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Reports, 2020, 2, 100148.	2.6	20
205	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liverâ€Related Cirrhosis. Hepatology, 2021, 73, 2238-2250.	3.6	20
206	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. Journal of Personalized Medicine, 2021, 11, 475.	1.1	20
207	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	2.6	20
208	Acute cholestatic hepatitis induced by nimesulide. Liver International, 1999, 19, 164-165.	1.9	19
209	<i>Campylobacter fetus</i> Peritonitis and Bacteremia in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis. Journal of Clinical Microbiology, 2010, 48, 336-337.	1.8	19
210	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. Scientific Reports, 2022, 12, 3418.	1.6	19
211	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Alimentary Pharmacology and Therapeutics, 2013, 37, 74-80.	1.9	18
212	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Annals of Hepatology, 2014, 13, 356-363.	0.6	18
213	Diagnostic accuracy of <scp>SCCA</scp> and <scp>SCCA</scp>â€IgM for hepatocellular carcinoma: A metaâ€analysis. Liver International, 2018, 38, 1820-1831.	1.9	18
214	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 2018, 16, 292-294.	2.4	18
215	Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World Journal of Gastroenterology, 2015, 21, 10776.	1.4	18
216	Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Revista Espanola De Enfermedades Digestivas, 2009, 101, 395-8, 399-402.	0.1	18

#	ARTICLE	IF	CITATIONS
217	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	1.9	18
218	Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1135-1141.	0.2	17
219	Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1236-1241.	0.5	17
220	Impact of liver injury on the severity of COVID-19: Systematic Review with Meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 125-135.	0.1	17
221	Anticoagulation therapy for recent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding. <i>Gastroenterology</i> , 2002, 122, 2095.	0.6	16
222	Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. <i>Journal of Clinical Virology</i> , 2008, 41, 264-269.	1.6	16
223	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2022, 76, 11-24.	1.8	16
224	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 264-269.	0.1	16
225	Brain biomolecules oxidation in portacaval-shunted rats. <i>Liver International</i> , 2011, 31, 964-969.	1.9	15
226	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 940-948.	1.8	15
227	Sarcoidosis, Sclerosing Cholangitis, and Chronic Atrophic Autoimmune Gastritis. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 162-165.	1.1	15
228	A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 552-558.	0.1	15
229	A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy. <i>Cancers</i> , 2022, 14, 192.	1.7	15
230	Acute Hepatitis After Starting Zinc Therapy in a Patient With Presymptomatic Wilson's Disease. <i>Hepatology</i> , 2000, 32, 877.	3.6	14
231	Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. <i>Digestive and Liver Disease</i> , 2007, 39, 262-266.	0.4	14
232	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. <i>Annals of Hepatology</i> , 2015, 14, 457-463.	0.6	14
233	Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 845-857.	1.0	14
234	Hepatitis B and NAFLD: Lives Crossed. <i>Annals of Hepatology</i> , 2017, 16, 185-187.	0.6	14

#	ARTICLE	IF	CITATIONS
235	Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 585425.	1.2	14
236	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
237	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr ^{-/-} .Leiden mice without attenuation of steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 8250.	1.6	14
238	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	3.2	14
239	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs. <i>World Journal of Gastroenterology</i> , 2006, 12, 5078.	1.4	14
240	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	1.9	14
241	Norfloxacin-Induced Acute Cholestatic Hepatitis in A Patient With Alcoholic Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2324-2325.	0.2	13
242	Treatment of chronic hepatitis C genotype 1 with peginterferon-2a (40kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 899-906.	1.9	13
243	THDP17 Decreases Ammonia Production through Glutaminase Inhibition. A New Drug for Hepatic Encephalopathy Therapy. <i>PLoS ONE</i> , 2014, 9, e109787.	1.1	13
244	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015, 35, 90-100.	1.9	13
245	Detecting liver fat from viscoelasticity: How good is CAP in clinical practice? The need for universal cut-offs. <i>Journal of Hepatology</i> , 2017, 66, 886-887.	1.8	13
246	Does the Antitumor Necrosis Factor-1 Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?. <i>Journal of Clinical Densitometry</i> , 2019, 22, 195-202.	0.5	13
247	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	1.9	13
248	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	1.6	13
249	Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. <i>Cancers</i> , 2021, 13, 6153.	1.7	13
250	Water-soluble extracts from edible mushrooms (<i>Agaricus bisporus</i>) as inhibitors of hepatitis C viral replication. <i>Food and Function</i> , 2019, 10, 3758-3767.	2.1	12
251	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1238-1247.	0.2	12
252	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.2	12

#	ARTICLE	IF	CITATIONS
253	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.1	12
254	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-63.	0.6	12
255	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015, 68, 56-60.	1.6	11
256	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , 2021, 5, 1051-1068.	2.0	11
257	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	2.7	11
258	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021, 75, 924-934.	1.8	11
259	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
260	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
261	Insulin Resistance Impairs Viral Dynamics Independently of Ethnicity or Genotypes. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 228-234.	1.1	10
262	Stanozolol-induced bland cholestasis. <i>GastroenterologÃa Y HepatologÃa</i> , 2014, 37, 71-72.	0.2	10
263	Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 9163.	1.4	10
264	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015, 16, 297-300.	2.2	10
265	Remission maintained by monotherapy after biological+immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 112-118.	1.4	10
266	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016, 17, 1587-1594.	0.6	10
267	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	1.5	10
268	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	1.9	10
269	Nuevas perspectivas terapÃ©uticas en la esteatohepatitis no alcohÃ³lica. <i>GastroenterologÃa Y HepatologÃa</i> , 2018, 41, 128-142.	0.2	10
270	Natural Extracts Abolished Lipid Accumulation in Cells Harboring non-favourable PNPLA3 genotype. <i>Annals of Hepatology</i> , 2018, 17, 242-249.	0.6	10

#	ARTICLE	IF	CITATIONS
271	Looking for a new name for Non-alcoholic fatty liver disease in Spanish: Esteatosis Hepática Metabólica (EHmet). <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 161-163.	0.1	10
272	Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. <i>Seminars in Liver Disease</i> , 2021, 41, 191-205.	1.8	10
273	Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3503.	1.2	10
274	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021, 8, 2004168.	5.6	10
275	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. <i>Medicine (United States)</i> , 2020, 99, e23506.	0.4	10
276	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016, 22, 5285.	1.4	10
277	Insulin Resistance and Response to Antiviral Therapy in Chronic Hepatitis C: Mechanisms and Management. <i>Digestive Diseases</i> , 2010, 28, 285-293.	0.8	9
278	Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 608-611.	0.6	9
279	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013, 58, S46.	1.8	9
280	Undetectable HCV RNA at treatment week 8 results in high sustained virological response in G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015, 22, 469-480.	1.0	9
281	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774341.	1.4	9
282	Entry of hepatitis C virus into the cell: A therapeutic target. <i>World Journal of Gastroenterology</i> , 2012, 18, 4481.	1.4	9
283	Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 161-9.	0.1	9
284	Experimental models for hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 536-541.	0.1	9
285	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
286	Prevalencia y significado clínico de los anticuerpos antifosfolipídicos en la hepatitis crónica por virus C. <i>Medicina Clínica</i> , 2000, 114, 367-370.	0.3	8
287	Hepatotoxicity induced by fosinopril. <i>Journal of Hepatology</i> , 2001, 35, 309-310.	1.8	8
288	509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study. <i>Journal of Hepatology</i> , 2004, 40, 150.	1.8	8

#	ARTICLE	IF	CITATIONS
289	The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 553-558.	1.5	8
290	Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. <i>Clinical Microbiology and Infection</i> , 2011, 17, 845-850.	2.8	8
291	Endoscopic closure of a rectovaginal fistula combining N-butyl-cyanoacrylate (Histoacryl) and Resolution clips. <i>Endoscopy</i> , 2011, 43, E133-E134.	1.0	8
292	HAVCR1 Gene Haplotypes and Infection by Different Viral Hepatitis C Virus Genotypes. <i>Vaccine Journal</i> , 2012, 19, 223-227.	3.2	8
293	Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. <i>Hepatology</i> , 2015, 61, 744-747.	3.6	8
294	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016, 64, S133.	1.8	8
295	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017, 153, 1448-1449.	0.6	8
296	Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization. <i>FASEB Journal</i> , 2019, 33, 7578-7587.	0.2	8
297	A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2019, 29, 983-989.	1.1	8
298	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2022, 117, 138-146.	0.2	8
299	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017, 9, 697.	0.8	8
300	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. <i>Annals of Hepatology</i> , 2015, 14, 457-63.	0.6	8
301	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. <i>Journal of Gastroenterology</i> , 2022, 57, 357-371.	2.3	8
302	Deciphering the Spectrum of Low-Grade Hepatic Encephalopathy in Clinical Practice. <i>Gastroenterology</i> , 2014, 146, 887-890.	0.6	7
303	Evolution of the incidence of inflammatory bowel disease in Southern Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 757-760.	0.1	7
304	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2018, 41, 328-349.	0.0	7
305	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-Î²1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	1.6	7
306	Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model. <i>Journal of Clinical Medicine</i> , 2021, 10, 2208.	1.0	7

#	ARTICLE	IF	CITATIONS
307	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021, 41, 95-104.	1.9	7
308	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 667354.	2.2	7
309	Lansoprazole-Induced Hepatic Dysfunction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1731-1731.	0.9	6
310	Macro-AST as cause of unknown hypertransaminaemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 103-104.	0.8	6
311	Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 761-765.	0.8	6
312	Propranolol-induced angioedema in a patient with chronic hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1182-1184.	0.5	6
313	APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others. <i>Journal of Hepatology</i> , 2011, 55, 1184-1186.	1.8	6
314	Insulin resistance and sustained virological response in hepatitis C: from bench to bedside. <i>Liver International</i> , 2011, 31, 1-3.	1.9	6
315	1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFN±2A AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2012, 56, S552.	1.8	6
316	Meta-analysis: pegylated interferon ±2a achieves higher early virological responses than ±2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1065-1073.	1.9	6
317	Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. <i>Annals of Hepatology</i> , 2017, 16, 179-181.	0.6	6
318	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 356-362.	0.7	6
319	PTPN22 C1858T Polymorphism and the Outcome of Hepatitis C Virus Infection. <i>Viral Immunology</i> , 2008, 21, 491-494.	0.6	5
320	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	1.8	5
321	Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1301-1308.	1.4	5
322	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	1.5	5
323	Long-term follow-up of patients with chronic hepatitis C treated with ±-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 792-799.	0.8	5
324	Endoscopic ultrasound-guided placement of plastic pigtail stents for the drainage of refractory malignant ascites. <i>Endoscopy International Open</i> , 2017, 05, E1096-E1099.	0.9	5

#	ARTICLE	IF	CITATIONS
325	Relationship Between Self-Perceived Health, Vitality, and Posttraumatic Growth in Liver Transplant Recipients. <i>Frontiers in Psychology</i> , 2019, 10, 1367.	1.1	5
326	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 921-930.	1.9	5
327	Simple noninvasive scoring systems and histological scores in predicting mortality in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	1.4	5
328	Results of a survey in Andalusian Endoscopy Units. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006, 98, 929-48.	0.1	5
329	Results of a survey about specific inflammatory bowel disease units in Andalusia. <i>Revista Espanola De Enfermedades Digestivas</i> , 2009, 101, 187-94.	0.1	5
330	Pancreatic Abscess Due To <i>Streptococcus Salivarius</i> After Dental Manipulation. <i>American Journal of Gastroenterology</i> , 1999, 94, 1987-1988.	0.2	4
331	HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003, 98, 1621-1626.	0.2	4
332	Case Report: Histologic Features of Steatohepatitis in Patients with a Clinical Diagnosis of Autoimmune Cholestasis. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1957-1961.	1.1	4
333	548 Sustained response in chronic hepatitis C reduces the risk to develop impaired fasting glucose and/or diabetes mellitus type 2. <i>Journal of Hepatology</i> , 2006, 44, S204.	1.8	4
334	1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2008, 48, S375.	1.8	4
335	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , 2015, 110, S850-S851.	0.2	4
336	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	0.8	4
337	Editorial: looking for patients at risk of cirrhosis in the general populationâ€”many needles in a haystack. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 692-694.	1.9	4
338	Hepatic encephalopathy and traffic accidents: Vigilance is needed!. <i>Journal of Hepatology</i> , 2019, 70, 590-592.	1.8	4
339	A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. <i>PLoS ONE</i> , 2016, 11, e0150569.	1.1	4
340	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 223-227.	0.1	4
341	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. <i>World Journal of Gastroenterology</i> , 2007, 13, 2187.	1.4	4
342	Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis. <i>European Journal of Internal Medicine</i> , 2022, 98, 53-60.	1.0	4

#	ARTICLE	IF	CITATIONS
343	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	1.9	4
344	Three-day intravenous triple therapy is not effective for the eradication of <i>Helicobacter pylori</i> infection in patients with bleeding gastro-duodenal ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 1023-1029.	1.9	3
345	Familial Mediterranean Fever Mimicking Fitz-Hugh-Curtis Syndrome. <i>American Journal of Gastroenterology</i> , 2003, 98, 701-701.	0.2	3
346	Pneumatic perforation of the cecum during diagnostic sigmoidoscopy. <i>Endoscopy</i> , 2007, 39, E183-E183.	1.0	3
347	[638] INFLUENCE OF INSULIN RESISTANCE AND RIBAVIRIN DOSAGE IN VIRAL DYNAMICS OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 TREATED WITH PEGINTERFERON AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2007, 46, S241.	1.8	3
348	513 DOUBLE-BLINDED CROSSOVER TRIAL ANALYZING THE USEFULNESS OF RIFAXIMIN IN THE TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY (MHE): AN INTERIM ANALYSIS. <i>Journal of Hepatology</i> , 2010, 52, S206-S207.	1.8	3
349	505 IBUPROFEN-ASSOCIATED HEPATOTOXICITY: ANALYSIS OF A CASE SERIES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011, 54, S206.	1.8	3
350	Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 619-625.	0.1	3
351	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	1.6	3
352	Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice. <i>Journal of Hepatology</i> , 2018, 68, S97-S98.	1.8	3
353	Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry. <i>Journal of Hepatology</i> , 2018, 68, S833.	1.8	3
354	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , 2018, 17, 864-870.	0.6	3
355	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 641-649.	0.1	3
356	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
357	PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019, 70, e133-e134.	1.8	3
358	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 427-433.	0.1	3
359	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.3	3
360	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	1.1	3

#	ARTICLE	IF	CITATIONS
361	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective. <i>World Journal of Virology</i> , 2021, 10, 301-311.	1.3	3
362	Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States. <i>Medicine (United States)</i> , 2021, 100, e28165.	0.4	3
363	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. <i>Gut</i> , 2003, 52, 915-915.	6.1	2
364	508 Insulin resistance, fibrosis and genotype are predictors of sustained response rate to pegylated interferon plus ribavirin in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2004, 40, 150.	1.8	2
365	230 Usefulness of the measurement of critical flicker frequency in the diagnosis of minimal hepatic encephalopathy (MHE). <i>Journal of Hepatology</i> , 2006, 44, S93.	1.8	2
366	566 Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40KD) (PEGASYS®) and ribavirin (COPEGUSA®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin. <i>Journal of Hepatology</i> , 2006, 44, S210-S211.	1.8	2
367	Different approaches to therapy of esophageal granular cell tumor (Abrikossoff tumor). <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 993-994.	0.6	2
368	1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). <i>Journal of Hepatology</i> , 2012, 56, S456.	1.8	2
369	Knowledge discovery of customer satisfaction and dissatisfaction using ontology-based text analysis of critical incident dialogues. , 2012, , .		2
370	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 699.	0.5	2
371	P833 QUERCETIN MODULATES LIPIDS DROPLETS IN Huh7 CELLS BEARING PNPLA3 GENOTYPE GG. <i>Journal of Hepatology</i> , 2014, 60, S348-S349.	1.8	2
372	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterology</i> , 2014, 37, 1-8.	0.2	2
373	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014, 60, S139.	1.8	2
374	P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS. <i>Journal of Hepatology</i> , 2014, 60, S452-S453.	1.8	2
375	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	1.1	2
376	Reply. <i>Gastroenterology</i> , 2015, 149, 1988-1989.	0.6	2
377	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 181-186.	1.8	2
378	PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibanor Trial. <i>Journal of Hepatology</i> , 2016, 64, S147.	1.8	2

#	ARTICLE	IF	CITATIONS
379	Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients with Cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, S257.	1.8	2
380	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. <i>Journal of Hepatology</i> , 2019, 70, e16-e17.	1.8	2
381	Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians. <i>Journal of Hepatology</i> , 2020, 73, S440.	1.8	2
382	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. <i>Digestive and Liver Disease</i> , 2020, 52, e33-e34.	0.4	2
383	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 301-307.	0.1	2
384	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 270-274.	0.1	2
385	Relationship between <i>H. pylori</i> and hepatitis A virus infection. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 220-221.	0.1	2
386	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 778-783.	0.1	2
387	Consenso AEEH Â«Consenso sobre mÃ©todos de detecciÃ³n y derivaciÃ³n de enfermedades hepÃ¡ticas prevalentes ocultasÂ». <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2023, 46, 236-247.	0.2	2
388	Prevalence and clinical significance of antiphospholipid antibodies (APA) in viral chronic liver disease. <i>Journal of Hepatology</i> , 2000, 32, 102.	1.8	1
389	Manganese level in patients with subclinical hepatic encephalopathy (SHE). <i>Journal of Hepatology</i> , 2000, 32, 150.	1.8	1
390	Transient Budd-Chiari Syndrome due to Iatrogenic Subcapsular Fluid Accumulation Following Thoracocentesis. <i>American Journal of Gastroenterology</i> , 2004, 99, 2281-2282.	0.2	1
391	603 Insulin resistance in co-infected HCV/HIV patients: A negative factor influencing sustained response to peginterferon plus ribavirin. <i>Journal of Hepatology</i> , 2006, 44, S223-S224.	1.8	1
392	Corrigendum to "Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome" [<i>J Hepatol</i> 49 (2008) 107-114]. <i>Journal of Hepatology</i> , 2009, 50, 636.	1.8	1
393	754 POSITIONAL CLONING IN GLS GENE: A MICROSATELLITE IN THE PROMOTER REGION PREDICTS THE RISK OF HEPATIC ENCEPHALOPATHY. <i>Journal of Hepatology</i> , 2009, 50, S277.	1.8	1
394	Reply:. <i>Hepatology</i> , 2010, 52, 1861-1862.	3.6	1
395	1175 IL28B GENETIC VARIANTS AND HEPATITIS VIRUS INFECTION BY DIFFERENT VIRAL GENOTYPES. <i>Journal of Hepatology</i> , 2010, 52, S454.	1.8	1
396	644 GENOME-WIDE ASSOCIATION AND HIGH THROUGHPUT GENOTYPE IMPUTATION STUDIES CONFIRM A SUSCEPTIBILITY LOCUS TO HCV INFECTION ON 6P22.1â€”P21.31. <i>Journal of Hepatology</i> , 2010, 52, S252.	1.8	1

#	ARTICLE	IF	CITATIONS
397	1340 HEPATITIS C VIRUS INFECTION ALTERS LIPID METABOLISM DEPENDING ON THE RS12979860 POLYMORPHISM IN THE IL28B GENE. <i>Journal of Hepatology</i> , 2011, 54, S529.	1.8	1
398	Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. <i>Annals of Hepatology</i> , 2011, 10, 241-243.	0.6	1
399	869 HEPATITIS C VIRUS MODIFIES THE EXPRESSION OF MICRO-RNAS ASSOCIATED WITH APOPTOSIS AND METABOLIC SYNDROME IN HUH7.5 CELLS. <i>Journal of Hepatology</i> , 2012, 56, S338-S339.	1.8	1
400	62 PHASE II HCVac STUDY OF TG4040 IMMUNOTHERAPEUTIC IN COMBINATION WITH PEGIFNa2a AND RIBAVIRIN IN GENOTYPE 1 CHC TREATMENT NAïVE PATIENTS: SVR24 FINAL RESULTS. <i>Journal of Hepatology</i> , 2013, 58, S28.	1.8	1
401	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>GastroenterologÅa Y HepatologÅa</i> , 2013, 36, 555-564.	0.2	1
402	799 EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS. <i>Journal of Hepatology</i> , 2013, 58, S326-S327.	1.8	1
403	Reply to: â€œRenal impairment and anemia during triple therapyâ€. <i>Journal of Hepatology</i> , 2014, 60, 1100-1101.	1.8	1
404	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	0.6	1
405	P0969 : Role of epigenetic factors in non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , 2015, 62, S709.	1.8	1
406	Reply to contribution on the topic of hypovitaminosis D in chronic hepatitis C. <i>Annals of Hepatology</i> , 2016, 15, 139-140.	0.6	1
407	Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, S499-S500.	1.8	1
408	A pragmatic algorithm to rule out Non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound. <i>Journal of Hepatology</i> , 2017, 66, S160-S161.	1.8	1
409	Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity. <i>Journal of Hepatology</i> , 2018, 68, S832-S833.	1.8	1
410	Genetic and functional analysis of FGF21 in NAFLD/NASH. <i>Journal of Hepatology</i> , 2018, 68, S342-S343.	1.8	1
411	Effect of hepatitis C sustained virological response on the endothelial dysfunction and the cardiovascular risk. HepCAR study. <i>Journal of Hepatology</i> , 2018, 68, S540-S541.	1.8	1
412	Pregnancy and autoimmune hepatitis: presentation and outcomes. <i>Journal of Hepatology</i> , 2018, 68, S233.	1.8	1
413	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2019, 42, 657-676.	0.0	1
414	Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2020, 52, e40-e41.	0.4	1

#	ARTICLE	IF	CITATIONS
415	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1443-1451.	1.0	1
416	Coping strategies predicting quality of life in diabetic and obese NAFLD patients. <i>European Journal of Public Health</i> , 2020, 30, .	0.1	1
417	Tricobezoar gástrico complicado con úlcera gástrica perforada. <i>Gastroenterología Y Hepatología</i> , 2004, 27, 560-560.	0.2	1
418	SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients: ACG International Award. <i>American Journal of Gastroenterology</i> , 2014, 109, S131.	0.2	1
419	Hepatitis aguda por montelukast. <i>Medicina Clínica</i> , 2003, 120, 239-239.	0.3	1
420	Cronkhite-Canada syndrome: a new case report of this enigmatic and infrequent disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010, 102, 208-15.	0.1	1
421	Dietary Approach to NAFLD. , 2020, , 271-287.		1
422	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	1.4	1
423	Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	1
424	Oral glutamine challenge in patients with subclinical hepatic encephalopathy. <i>Journal of Hepatology</i> , 2001, 34, 75.	1.8	0
425	Host and viral factors in hepatocyte steatosis detected in chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 175.	1.8	0
426	Oral glutamine challenge correlates with minimal hepatic encephalopathy and predicts overt episodes. <i>Journal of Hepatology</i> , 2002, 36, 13.	1.8	0
427	Role of leptin and hepatic stellate cell (HSC) in the development of steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 126.	1.8	0
428	Insulin Resistance and Hepatitis C. <i>Gastroenterology</i> , 2005, 128, 2178.	0.6	0
429	93 Amoxicillin-clavulanate (AC) associated hepatotoxicity: Analysis of a single country large cohort prospectively identified. <i>Journal of Hepatology</i> , 2006, 44, S41.	1.8	0
430	182 Protein oxidation in astrocyte of porto-caval shunted rats: Role of oxidative stress in hepatic encephalopathy. <i>Journal of Hepatology</i> , 2006, 44, S76.	1.8	0
431	669 Chronic liver damage after an episode of idiosyncratic drug induced liver injury (DILI). <i>Journal of Hepatology</i> , 2006, 44, S247.	1.8	0
432	[246] HAPLOTYPES TACG AND CACG FROM GLUTAMINASE GENE PROTECT AGAINST HEPATIC ENCEPHALOPATHY. <i>Journal of Hepatology</i> , 2007, 46, S100.	1.8	0

#	ARTICLE	IF	CITATIONS
433	Pathogenesis and natural course of hepatic steatosis and insulin resistance in patients with hepatitis C. <i>Current Hepatitis Reports</i> , 2008, 7, 113-119.	0.3	0
434	290 INSULIN RESISTANCE PREDICTS RISK FOR THE DEVELOPMENT OF VARICEAL BLEEDING. <i>Journal of Hepatology</i> , 2008, 48, S116.	1.8	0
435	593 SMOKING AND HEPATITIS C: INFLUENCE ON FIBROSIS PROGRESSION AND SUSTAINED RESPONSE. <i>Journal of Hepatology</i> , 2008, 48, S221-S222.	1.8	0
436	894 COMBINED GLUTATHIONE-S-TRANSFERASE M1 AND T1 GENETIC POLYMORPHISM AND SUSCEPTIBILITY TO DEVELOP DRUG-INDUCED IDIOSYNCRATIC LIVER INJURY (DILI). <i>Journal of Hepatology</i> , 2008, 48, S335-S336.	1.8	0
437	895 THE INFLUENCE OF AGE AND GENDER IN THE BIOCHEMICAL EXPRESSION OF IDIOSYNCRATIC LIVER INJURY. <i>Journal of Hepatology</i> , 2008, 48, S336.	1.8	0
438	Reply:. <i>Hepatology</i> , 2009, 50, 2055-2055.	3.6	0
439	306 ASSOCIATION OF MANGANESE SUPEROXIDE DISMUTASE FUNCTIONAL POLYMORPHISM (SOD2 V16A) WITH IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY. <i>Journal of Hepatology</i> , 2009, 50, S119-S120.	1.8	0
440	312 GENOTYPE DISTRIBUTION OF THE HEPATIC CANALICULAR TRANSPORTER ABCC2 &T POLYMORPHISM IS NOT RELATED TO DRUG-INDUCED IDIOSYNCRATIC LIVER INJURY (DILI). RELEVANCE OF ETHNIC VARIANTS IN EUROPEANS. <i>Journal of Hepatology</i> , 2009, 50, S122.	1.8	0
441	891 IMPORTANCE OF HLA-DQB1*0301 AS PREDICTIVE FACTOR OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC), GENOTYPE-1, TREATED WITH PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV). <i>Journal of Hepatology</i> , 2009, 50, S324.	1.8	0
442	Metformin improves sustained virologic response in difficult-to-cure hepatitis C: More questions than answers. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	0
443	1138 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI): FOLLOW-UP IN A COHORT OF PATIENTS IDENTIFIED IN 24 TERTIARY CARE CENTRES IN SPAIN. <i>Journal of Hepatology</i> , 2010, 52, S440.	1.8	0
444	161 THDP-17 INHIBITS THE GLUTAMINASE ACTIVITY IN CACO-2 CELL CULTURES. <i>Journal of Hepatology</i> , 2010, 52, S70-S71.	1.8	0
445	503 DIFFERENTIAL PROTEIN EXPRESSION IN THE CEREBELLUM OF PORTOCAVAL-SHUNTED RATS: A DIGE/MS STUDY. <i>Journal of Hepatology</i> , 2010, 52, S203.	1.8	0
446	519 IGF-1 REPLACEMENT THERAPY IN RATS WITH HEPATIC ENCEPHALOPATHY INDUCED BY PORTACAVAL SHUNT. <i>Journal of Hepatology</i> , 2010, 52, S208-S209.	1.8	0
447	155 THDP-17 INHIBITS SELECTIVELY THE K-TYPE INTESTINAL GLUTAMINASE, BUT NOT THE TYPE-L IN VITRO AND IN VIVO. <i>Journal of Hepatology</i> , 2011, 54, S67.	1.8	0
448	684 EFFECTS OF CHEMICAL MOIETIES AND POLYMORPHISMS IN THE HUMAN ABC TRANSPORTER ABCB1 (P-GLYCOPROTEIN/MDR1) IN DRUG-INDUCED LIVER INJURY. <i>Journal of Hepatology</i> , 2011, 54, S275.	1.8	0
449	777 ROLE OF RAPAMYCIN AS MTOR INHIBITOR IN VITRO AND ITS USE IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S312-S313.	1.8	0
450	Hepatitis C Virus and Statins: Is There a Role?. <i>Current Hepatitis Reports</i> , 2011, 10, 162-167.	0.3	0

#	ARTICLE	IF	CITATIONS
451	98 OPTICAL ANALYSIS OF LIVER MAGNETIC RESONANCE IMAGES BASED ON NEURAL NETWORKS FOR THE DETERMINATION OF FIBROSIS STAGE AND DISTRIBUTION IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Journal of Hepatology, 2012, 56, S42-S43.	1.8	0
452	122 HEPATITIS C VIRUS MODULATES LDL RECEPTOR (LDLR) GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS ACCORDING TO VIRAL CLEARANCE. Journal of Hepatology, 2012, 56, S54.	1.8	0
453	839 HEPATITIS C VIRUS MODIFIES PROTEIN AND GENE EXPRESSION OF THE INSULIN SIGNALING PATHWAY IN VIVO AND IN VITRO. Journal of Hepatology, 2012, 56, S327-S328.	1.8	0
454	908 FACTORS INVOLVED IN SUSTAINED VIRAL RESPONSE (SVR) ACHIEVEMENT IN PATIENTS WITH FAVORABLE IL28B CC GENOTYPE IN HEPATITIS C. Journal of Hepatology, 2012, 56, S353-S354.	1.8	0
455	923 INTERACTION BETWEEN RS12979860 POLYMORPHISM OF IL28B GENE WITH BASELINE PREDICTIVE FACTORS OF RESPONSE TO TREATMENT IN PATIENTS WITH HEPATITIS C. Journal of Hepatology, 2012, 56, S359-S360.	1.8	0
456	924 A GENOME-WIDE ASSOCIATION STUDY IDENTIFIED A NOVEL SUSCEPTIBILITY LOCUS GENE PBK (RS) Tj ETQq0 0 0 rgBT /Overlock 1 Hepatology, 2012, 56, S360.	1.8	0
457	Peginterferon alpha 2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1705-1710.	1.4	0
458	1109 HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY. Journal of Hepatology, 2012, 56, S437.	1.8	0
459	1378 EFFECT OF ABCC2 HAPLOTYPES ON INDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) SUSCEPTIBILITY. Journal of Hepatology, 2012, 56, S541.	1.8	0
460	893 EARLY VIROLOGICAL RESPONSE RATES IN MONOINFECTED PATIENTS WITH HCV AND COINFECTED WITH HCV/HIV, GENOTYPES 1&4 TREATED WITH PEGINTERFERON alpha 2a AND RIBAVIRIN. OPTIM STUDY. Journal of Hepatology, 2013, 58, S367-S368.	1.8	0
461	1336 NON-ALCOHOLIC STEATOHEPATITIS INCREASES THE PRODUCTION OF ANTIBODIES AGAINST OXIDIZED LDL, ATHEROSCLEROSIS AND CARDIOVASCULAR RISK. Journal of Hepatology, 2013, 58, S538-S539.	1.8	0
462	1172 FUNCTIONAL ANALYSIS OF THE DIACYLGLYCEROL ACYLTRANSFERASE ACTIVITY-1 (DGAT1) IN THE REPLICATION OF HEPATITIS C VIRUS: EFFECT OF QUERCETIN. Journal of Hepatology, 2013, 58, S476-S477.	1.8	0
463	1038 ROLE OF GENE AND microRNAs EXPRESSION RELATED TO HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A HCV-INDUCED MODEL IN VITRO. EFFECT OF METFORMIN. Journal of Hepatology, 2013, 58, S426-S427.	1.8	0
464	18 DETERMINATION OF FIBROSIS STAGE AND STEATOHEPATITIS IN PATIENTS WITH NAFLD BY OPTICAL ANALYSIS OF MAGNETIC RESONANCE IMAGES COMBINED WITH ARTIFICIAL NEURAL NETWORKS (FIBROMRI) Tj ETQq0 0 0 rgBT /Overlo	1.8	0
465	894 IL28B-BASED MODEL FOR PREDICTION OF WEEK 4 VIRAL RESPONSE IN PEGINTERFERON-alfa2a + RIBAVIRIN TREATED HEPATITIS C GENOTYPE 1&4. FINAL REPORT WEEK 4 OPTIM STUDY. Journal of Hepatology, 2013, 58, S368.	1.8	0
466	Insulin resistance, telaprevir, and virological response in hepatitis C: The debate must go on. Hepatology, 2013, 58, 1874-1876.	3.6	0
467	Cirrhosis is less cirrhosis without virus C. Annals of Hepatology, 2013, 12, 341-342.	0.6	0
468	P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2014, 60, S349-S350.	1.8	0

#	ARTICLE	IF	CITATIONS
469	O150 LOSS OF GATA4 IN HEPATIC STELLATE CELLS PROMOTES LIVER FIBROSIS. Journal of Hepatology, 2014, 60, S62.	1.8	0
470	P479 GLUTAMINASE GENE ALTERATION DETERMINES THE ABILITY TO PREDICT OVERT HEPATIC ENCEPHALOPATHY BOUTS BY CRITICAL FLICKER FREQUENCY AND ORAL GLUTAMINE CHALLENGE. Journal of Hepatology, 2014, 60, S229.	1.8	0
471	Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens. Value in Health, 2014, 17, A532.	0.1	0
472	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions. Value in Health, 2014, 17, A367.	0.1	0
473	P213 REGULATION OF THE AKT/MTOR PATHWAY BY METFORMIN IN HEPATOCELLULAR CARCINOMA DEVELOPMENT UPON HCV INFECTION. Journal of Hepatology, 2014, 60, S137.	1.8	0
474	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH "LATIN-AMERICAN DILI REGISTRY. Journal of Hepatology, 2014, 60, S169.	1.8	0
475	P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES. Journal of Hepatology, 2014, 60, S310-S311.	1.8	0
476	P673 DETECTION AND DERIVATION RATE AFTER PEER-TO-PEER TRAINING SESSIONS IN PRIMARY CARE ON THE SCREENING OF HEPATITIS B. Journal of Hepatology, 2014, 60, S293.	1.8	0
477	P1142 META-ANALYSIS: ROLE OF INSULIN SENSITIZERS ADDED TO PEGINTERFERON AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C. Journal of Hepatology, 2014, 60, S463.	1.8	0
478	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. Journal of Hepatology, 2014, 60, S169.	1.8	0
479	O042 : Weight loss intensity is strongly associated to improvement of histological parameters in patients with nonalcoholic steatohepatitis after 52 weeks of lifestyle modification. Journal of Hepatology, 2015, 62, S209-S210.	1.8	0
480	Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). Clinical Therapeutics, 2015, 37, e126-e127.	1.1	0
481	P0122 : Type 2 diabetes reduces overall survival and increases the risk of hepatic decompensation in HCV-related liver cirrhosis. Results from a prospective long-term study during 8 years. Journal of Hepatology, 2015, 62, S346.	1.8	0
482	P0984 : Development and validation of a simple clinical prediction model to identify patients with nonalcoholic steatohepatitis resolution after 52 weeks of lifestyle modification. Journal of Hepatology, 2015, 62, S715-S716.	1.8	0
483	P0215 : Metformin reduces hyperammonemia in portacaval shunted rats inhibiting glutaminase activity. Journal of Hepatology, 2015, 62, S386-S387.	1.8	0
484	P0169 : Critical flicker frequency predicts survival in patients with liver cirrhosis. Journal of Hepatology, 2015, 62, S366.	1.8	0
485	P0698 : Quercetin modifies lipid droplet morphology and impairs hepatitis C viral life-cycle steps from assembly to replication steps. Journal of Hepatology, 2015, 62, S584.	1.8	0
486	P0736 : Impact of physical activity on oxidative stress in patients with hepatitis C. Journal of Hepatology, 2015, 62, S600-S601.	1.8	0

#	ARTICLE	IF	CITATIONS
487	P0862 : First real clinical practice data on sofosbuvir, simeprevir and daclatasvir with HCV-chronically infected patients in Spain: The HepatiC registry experience. Journal of Hepatology, 2015, 62, S663-S664.	1.8	0
488	P0880 : Pharmacogenomic study to predict ribavirin and protease-inhibitor-related anemia in hepatitis C. Journal of Hepatology, 2015, 62, S671-S672.	1.8	0
489	P0938 : Olive oil consumption ameliorates non-alcoholic steatohepatitis induced by hypercaloric and hyperlipidic western diets. Journal of Hepatology, 2015, 62, S696-S697.	1.8	0
490	P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. Journal of Hepatology, 2015, 62, S761-S762.	1.8	0
491	Reply. Hepatology, 2016, 64, 2266-2267.	3.6	0
492	A Post-Hoc Analysis of the Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy. Journal of Hepatology, 2016, 64, S192.	1.8	0
493	A Non-Invasive Lipidomic Test Accurately Discriminates Non-Alcoholic Steatohepatitis from Steatosis: A Blind Validation Study. Journal of Hepatology, 2016, 64, S478.	1.8	0
494	The FTO rs1421085 T > C Polymorphism is Associated with the Severity of Non-Alcoholic Fatty Liver. Journal of Hepatology, 2016, 64, S490-S491.	1.8	0
495	Impact of GWAS-Identified Common Variants on Histopathological Features of Non-Alcoholic Fatty Liver Disease Patients. Journal of Hepatology, 2016, 64, S495-S496.	1.8	0
496	HCV Genotype 3: Meta-Analysis with Available Treatment Options. Journal of Hepatology, 2016, 64, S777.	1.8	0
497	Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide from the Spanish and Latin-American DILI Registries. Journal of Hepatology, 2016, 64, S239-S240.	1.8	0
498	Development and Validation of a Non-Invasive Model for Predicting Fibrosis Resolution One Year after Lifestyle Intervention for Biopsy-Proven Non-Alcoholic Steatohepatitis. Journal of Hepatology, 2016, 64, S480.	1.8	0
499	High Resolution Analysis for Genotypes and Subgenotypes Identification in Hepatitis C Reveals the Importance of Mixed Infections for Optimal Therapy. Journal of Hepatology, 2016, 64, S616-S617.	1.8	0
500	Impact of Basal Comorbidities on the Overall Benefit of DAA Therapy in Hepatitis C. Journal of Hepatology, 2016, 64, S777-S778.	1.8	0
501	Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry. Journal of Hepatology, 2017, 66, S399.	1.8	0
502	HepCom: impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C. Journal of Hepatology, 2017, 66, S514-S515.	1.8	0
503	Idiosyncratic Drug-Induced Liver Injury: A 20-Year Update of the Cases Enrolled By the Spanish DILI Registry. Clinical Therapeutics, 2017, 39, e57.	1.1	0
504	Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy. Journal of Hepatology, 2017, 66, S670-S671.	1.8	0

#	ARTICLE	IF	CITATIONS
505	Critical Flicker Frequency Predicts Progression among Stages of Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, S62.	0.4	0
506	High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2017, 66, S311.	1.8	0
507	Time in HE in cirrhotic patients with an acute episode (â%¥grade 2) determines short and long-term survival. <i>Journal of Hepatology</i> , 2017, 66, S372.	1.8	0
508	Oral glutamine challenge predicts risk and defines hepatic encephalopathy types. <i>Journal of Hepatology</i> , 2017, 66, S378-S379.	1.8	0
509	Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 66, S155-S156.	1.8	0
510	Genetic determinants influencing on overt hepatic encephalopathy and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2017, 66, S144.	1.8	0
511	New therapeutic perspectives in non-alcoholic steatohepatitis. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2018, 41, 128-142.	0.0	0
512	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years. <i>Journal of Hepatology</i> , 2018, 68, S218-S219.	1.8	0
513	Genetic factors of hepatic encephalopathy on patients with cirrhosis: candidate gene study. <i>Journal of Hepatology</i> , 2018, 68, S472.	1.8	0
514	Critical flicker frequency improves its diagnostic and predictive accuracy of hepatic encephalopathy by decreasing the dispersion between measures. <i>Journal of Hepatology</i> , 2018, 68, S743.	1.8	0
515	THU-466-Epigenetic regulation of gene expression in a HCC-NASH murine model. <i>Journal of Hepatology</i> , 2019, 70, e364-e365.	1.8	0
516	FRI-299-Transcriptomic and epigenetic characterization of a NAFLD murine model. <i>Journal of Hepatology</i> , 2019, 70, e526-e527.	1.8	0
517	PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study. <i>Journal of Hepatology</i> , 2019, 70, e35-e36.	1.8	0
518	THU-438-The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e350.	1.8	0
519	SAT-105-Rising economic burden following the diagnosis of compensated cirrhosis among hospitalized patients with Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in Spain. <i>Journal of Hepatology</i> , 2019, 70, e675.	1.8	0
520	PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS. <i>Journal of Hepatology</i> , 2019, 70, e17-e18.	1.8	0
521	SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients. <i>Journal of Hepatology</i> , 2019, 70, e663-e664.	1.8	0
522	SAT-151-What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?. <i>Journal of Hepatology</i> , 2019, 70, e697-e698.	1.8	0

#	ARTICLE	IF	CITATIONS
523	551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB95.	0.5	0
524	FRI-318-Effects of fatty acids and polyphenols from extra virgin olive oil in a murine animal dietary model knockout for the LDL receptor. <i>Journal of Hepatology</i> , 2019, 70, e536.	1.8	0
525	Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. <i>Digestive and Liver Disease</i> , 2019, 51, e25-e26.	0.4	0
526	IDDF2019-ABS-0131-...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
527	IDDF2019-ABS-0133-...Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
528	P: -Genetic Fingerprint of Hepatic Encephalopathy Risk in Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019, 114, S1-S1.	0.2	0
529	Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. <i>Digestive and Liver Disease</i> , 2020, 52, e41-e42.	0.4	0
530	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , 2021, 11, e275.	1.7	0
531	COVID-19 and the liver: The chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 555.	0.1	0
532	Reply to: -The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD- <i>Journal of Hepatology</i> , 2021, 74, 971-972.	1.8	0
533	EASL international recognition award recipient 2021: Prof. Dr. Nahum MÃ©ndez-SÃ¡nchez. <i>Journal of Hepatology</i> , 2021, 75, 10-11.	1.8	0
534	Entwicklung und Validierung des NAFLD Cirrhosis Score (NCS) zur Separierung von fortgeschrittener Fibrose und Zirrhose. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
535	Pathogenesis of hyperintensity in the globus pallidus (HIGP) in cirrhotic patients. <i>Journal of Hepatology</i> , 2001, 34, 61.	1.8	0
536	Bursitis bacteriana espontÃ¡nea en un paciente con cirrosis hepÃ¡tica. <i>Medicina ClÃ¡nica</i> , 2003, 120, 435-435.	0.3	0
537	Peritonitis bacteriana espontÃ¡nea por <i>Streptococcus anginosus</i> . <i>GastroenterologÃ¡a Y HepatologÃ¡a</i> , 2004, 27, 151-151.	0.2	0
538	Tumor estromal de localizaciÃ³n gÃ¡strica. <i>GastroenterologÃ¡a Y HepatologÃ¡a</i> , 2004, 27, 429-429.	0.2	0
539	Hepatitis C: are there any options for non-responders?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2005, 97, 299-305.	0.1	0
540	Invasive pulmonary aspergillosis in a young man with Crohn's disease. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2012, 33, 294-295.	0.0	0

#	ARTICLE	IF	CITATIONS
541	Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients. American Journal of Gastroenterology, 2014, 109, S133-S134.	0.2	0
542	1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). Diabetes, 2020, 69, .	0.3	0
543	1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs). Diabetes, 2020, 69, .	0.3	0
544	The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries. , 2020, 58, .		0
545	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.1	0
546	Polycystic liver in the adult (PLA) in Spain: analysis of a structured survey analyzing the experience and attitude of gastroenterologists in Spain. Revista Espanola De Enfermedades Digestivas, 2014, 106, 263-75.	0.1	0
547	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. American Journal of Gastroenterology, 2022, 117, 819-819.	0.2	0